25 completed, 8 unknown, 6 terminated, 3 recruiting. 17 Phase 2, 9 Phase 3, 7 Not applicable, 7 Phase 1, 5 Phase 4.
Follow Interferons: new trials by email Literature Review of Interferons trials Research Report on Interferons
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy SV-BR-1-GM Vaccine, Cyclophosphamide, Pembrolizumab - Brain Metastases, Leptomeningeal Metastasis | Phase 1 | Withdrawn | Medical College of Wisconsin | 2026-06-15 | 2026-06-17 | |
| Antiviral Therapy in Infants With HBV Infection Lamivudine, Interferon - HBV | Phase 4 | Not yet recruiting | Beijing 302 Hospital | 60 | 2024-08-01 | 2024-07-23 |
| Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy nucleoside analogues or interferon - HBV, HCC | Not yet recruiting | Wen-hong Zhang | 5000 | 2023-12-01 | 2023-07-28 | |
| Assessing the Effectiveness and Safety of Interferon Bladder Infusion for the Treatment of Interstitial Cystitis Interferon, Sodium Hyaluronate, Sodium Chloride Injection - Interstitial Cystitis | Phase 2 / Phase 3 | Unknown | West China Hospital | 129 | 2023-10-15 | 2023-09-15 |
| Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia Interferon - Acute Myeloid Leukemia | Phase 3 | Recruiting | Peking University People's Hospital | 96 | 2023-01-01 | 2025-01-31 |
| Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy Interferon, nucleoside analogues - Chronic Hepatitis B, COVID-19 Infection | Unknown | Beijing Ditan Hospital | 600 | 2022-09-01 | 2023-03-31 | |
| Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS Ofatumumab, First line DMT - Multiple Sclerosis | Phase 3 | Completed | Novartis Pharmaceuticals | 185 | 2021-07-23 | 2026-03-03 |
| A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate - Relapsing Multiple Sclerosis (RMS) | Phase 4 | Terminated | Novartis Pharmaceuticals | 24 | 2021-06-10 | 2025-05-16 |
| Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS). DMT - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Not applicable | Unknown | Amsterdam UMC, location VUmc | 130 | 2020-07-01 | 2020-10-19 |
| A Cohort Study on Long-term Clinical Outcomes of Antiviral Therapy in Patients With Chronic Hepatitis B and Cirrhosis interferon - Chronic Hepatitis b | Unknown | Beijing Ditan Hospital | 10000 | 2020-04-01 | 2020-03-10 | |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: - Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension | Recruiting | Duke University | 5000 | 2020-03-05 | 2026-08-21 | |
| MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera Ruxolitinib, Hydroxycarbamide, Interferon-Alpha - Polycythemia Vera | Phase 3 | Recruiting | University of Birmingham | 586 | 2019-10-25 | 2026-10-26 |
| Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C Interferon, ribavirin, DAAs - Chronic Hepatitis C | Unknown | Beijing Ditan Hospital | 1000 | 2019-08-01 | 2019-08-28 | |
| Czech Pharmaco-epidemiological Study on Disease Modifying Drugs interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab - Multiple Sclerosis | Completed | IMPULS Endowment Fund | 17478 | 2019-01-01 | 2023-03-09 | |
| Cohort Study of Efficacy and Safety of Interferon Intermittent Treatment of Chronic Hepatitis B interferon - Chronic Hepatitis B | Completed | Beijing Ditan Hospital | 400 | 2018-06-01 | 2019-07-23 | |
| Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod - Multiple Sclerosis, Relapsing-Remitting | Not applicable | Completed | Johns Hopkins University | 900 | 2018-05-02 | 2026-09-23 |
| Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention Interferon, nucleoside analogues - Chronic Hepatitis B Infection | Unknown | Beijing Ditan Hospital | 420 | 2017-05-01 | 2019-07-23 | |
| The Curative Effect and Security of Interferon Combined Resveratrol on HBeAg Positive Chronic Hepatitis B Patients Interferon, Interferon+resveratrol - Hepatitis B, Interferon | Not applicable | Completed | The First Hospital of Jilin University | 228 | 2016-06-01 | 2020-10-14 |
| Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer CG0070 Adenovirus Vector, Control Arm: Quadruple Choice - Transitional Cell Carcinoma, Bladder Cancer | Phase 2 / Phase 3 | Terminated | CG Oncology, Inc. | 22 | 2014-03-01 | 2021-04-14 |
| A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma imatinib, Interferon - Melanoma | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 40 | 2012-08-01 | 2013-02-04 |
Showing 20 of 47. Sign in to see all of them.
Neoplasms (5) · Carcinoma, Renal Cell (4) · Hepatitis B, Chronic (4) · Hepatitis C, Chronic (4) · Melanoma (4) · Multiple Sclerosis (4) · COVID-19 (3) · Hepatitis C (3) · Lymphoma (3) · Lymphoma, Follicular (3) · Carcinoma, Hepatocellular (2) · Coronavirus Infections (2) · Fibrosis (2) · Hepatitis B (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2)
Beijing Ditan Hospital (5) · Bayer (3) · M.D. Anderson Cancer Center (3) · Novartis Pharmaceuticals (2) · The Cleveland Clinic (2) · The First Hospital of Jilin University (2) · Aarhus University Hospital (1) · Aga Khan University (1) · Ainos, Inc. (f/k/a Amarillo Biosciences Inc. (1) · Amsterdam UMC, location VUmc (1) · Assistance Publique - Hôpitaux de Paris (1) · Austrian Breast & Colorectal Cancer Study Group (1) · Beijing 302 Hospital (1) · CG Oncology, Inc. (1) · Central European Cooperative Oncology Group (1)
United States (13) · China (11) · France (5) · Spain (4) · Austria (3) · United Kingdom (3) · Germany (2) · Italy (2) · Poland (2) · Belgium (1) · Canada (1) · Czechia (1) · Denmark (1) · India (1) · Ireland (1)
Ernest C. Borden, MD (2) · Yao Xie, Doctor (2) · Agop Y. Bedikian, MD,BS (1) · Alex W Yeung, MBBS (1) · Amar Safdar, MD (1) · Annette Alaeus, MD;PhD (1) · Bertrand Coiffier, MD (1) · Catherine Sebban, MD (1) · Cervantes Francisco, Dr (1) · Charlie Xiang, Professor (1) · Chi Hornik (1) · Christopher J Melani, M.D. (1) · Claire Harrison (1) · Ellen M. Mowry, MD, MCR (1)
PMID 10586336, PMID 18495540, PMID 19171708, PMID 20220063, PMID 20608766, PMID 24237300, PMID 26700705, PMID 33407619, PMID 36110295, PMID 37011643, PMID 37146227, PMID 38587846, PMID 38654416, PMID 39652340, PMID 42350969
P30CA043703 (2), 2005 (1)